Marker Therapeutics, Inc.

Marker Therapeutics, Inc.verified

MRKR

Price:

$3.38

Market Cap:

$30.16M

Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of various T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications in the United States. Its MultiTAA-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens and kill tumor cells expressing tumor-associated antigens. The company's MultiTAA-specific T cell therapies include autologous T cells for the treatment of lymphoma, and various solid tumors; allogeneic T cells for the treatment of acute myeloid leukemia and...[Read more]

Industry

Biotechnology

IPO Date

2002-07-16

Stock Exchange

NASDAQ

Ticker

MRKR

The Enterprise Value as of December 2024 (TTM) for Marker Therapeutics, Inc. (MRKR) is 21.16M

According to Marker Therapeutics, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 21.16M. This represents a change of -29.40% compared to the average of 29.97M of the last 4 quarters.

Marker Therapeutics, Inc. (MRKR) Historical Enterprise Value (quarterly & annually)

How has MRKR Enterprise Value performed in the past?

The mean historical Enterprise Value of Marker Therapeutics, Inc. over the last ten years is 35.97M. The current 21.16M Enterprise Value has changed 5.78% with respect to the historical average. Over the past ten years (40 quarters), MRKR's Enterprise Value was at its highest in in the June 2019 quarter at 314.33M. The Enterprise Value was at its lowest in in the March 2015 quarter at 4.40M.

Quarterly (TTM)
Annual

Average

35.97M

Median

32.64M

Minimum

4.24M

Maximum

87.87M

Marker Therapeutics, Inc. (MRKR) Enterprise Value by Quarter and Year

Discovering the peaks and valleys of Marker Therapeutics, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Maximum Annual Increase = 367.90%

Maximum Annual Enterprise Value = 87.87M

Minimum Annual Increase = -57.27%

Minimum Annual Enterprise Value = 4.24M

Quarterly (TTM)
Annual
YearEnterprise ValueChange
202333.34M84.82%
202218.04M-57.27%
202142.21M-28.59%
202059.11M-32.73%
201987.87M98.75%
201844.21M38.46%
201731.93M69.08%
201618.89M-4.83%
201519.84M367.90%
20144.24M-25.67%

Marker Therapeutics, Inc. (MRKR) Average Enterprise Value

How has MRKR Enterprise Value performed in the past?

The current Enterprise Value of Marker Therapeutics, Inc. (MRKR) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

3-year avg

31.20M

5-year avg

48.12M

10-year avg

35.97M

Marker Therapeutics, Inc. (MRKR) Enterprise Value vs. Peers

How is MRKR’s Enterprise Value compared to its peers?

Marker Therapeutics, Inc.’s Enterprise Value is less than Lumos Pharma, Inc. (24.19M), less than Exicure, Inc. (50.55M), greater than Protagenic Therapeutics, Inc. (2.29M), less than PMV Pharmaceuticals, Inc. (40.53M), less than Anebulo Pharmaceuticals, Inc. (40.61M), less than Miromatrix Medical Inc. (90.06M), less than ZIVO Bioscience, Inc. (78.24M), less than Bionomics Limited (1.26B), less than Agenus Inc. (74.89M), less than Icosavax, Inc. (713.87M), greater than Galera Therapeutics, Inc. (-6823234.00), less than Edgewise Therapeutics, Inc. (2.76B), less than RenovoRx, Inc. (21.40M), less than Tempest Therapeutics, Inc. (33.01M), less than Ikena Oncology, Inc. (37.04M), less than Catalyst Biosciences, Inc. (1.01B), less than Acrivon Therapeutics, Inc. Common Stock (154.58M), less than Alector, Inc. (178.66M), less than Aadi Bioscience, Inc. (44.35M), less than Keros Therapeutics, Inc. (165.48M), less than Aerovate Therapeutics, Inc. (44.50M),

Build a custom stock screener for Marker Therapeutics, Inc. (MRKR) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Marker Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Custom stock screener in Wisesheets

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Marker Therapeutics, Inc. (MRKR) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Marker Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Custom stock templates in Wisesheets

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.

Frequently asked questions❓

What is the Enterprise Value?

How can you use the Enterprise Value?

What is Marker Therapeutics, Inc.'s Enterprise Value?

What is the highest Enterprise Value for Marker Therapeutics, Inc. (MRKR)?

What is the 3-year average Enterprise Value for Marker Therapeutics, Inc. (MRKR)?

What is the 5-year average Enterprise Value for Marker Therapeutics, Inc. (MRKR)?

How does the current Enterprise Value for Marker Therapeutics, Inc. (MRKR) compare to its historical average?